Virologic Responses to Add-on Adefovir Dipivoxil Treatment versus Entecavir Mono

StephenW

J Pediatr Gastroenterol Nutr. 2012 Jun 8. [Epub ahead of print]
Virologic Responses to Add-on Adefovir Dipivoxil Treatment versus Entecavir Monotherapy in Children with Lamivudine-resistant Chronic Hepatitis B.Chu M, Cho SM, Choe BH, Cho MH, Kwon S, Lee WK.
Source*
Department of Pediatrics †Preventive Medicine, Kyungpook National University School of Medicine, Daegu, Korea.

Abstract
PURPOSE: To compare the virologic response to adefovir (ADV) add-on therapy with switching to entecavir (ETV) monotherapy in children and adolescents with chronic hepatitis B who have developed lamivudine (LAM) resistance during LAM treatment.
METHODS: Twenty-seven consecutive patients with chronic hepatitis B who had developed lamivudine resistance during LAM treatment were included. Of these 27 patients, 8 patients were treated with the addition of ADV to ongoing LAM and 8 patients were treated by switching to ETV monotherapy and each of these 16 patients were compared to the 11 patients who were treated by switching to ADV alone, as a historical control. Therapeutic responses to treatment were evaluated at 12, 24, 36, 48 weeks from the initiation of therapy by measuring the decrement of HBV DNA titers.
RESULTS: The therapeutic period for HBV DNA titer decrement (>2log10 IU/mL) was significantly shorter in both the LAM+ADV group and the ETV group than in the ADV group (p = 0.008). However, there was no significant difference between the LAM+ADV group and the ETV group. The rate of virologic response, defined as decrement in HBV DNA titer to undetectable levels at 24 weeks was significantly higher in both the LAM+ADV group and the ETV group than in the ADV group (p = 0.029).
CONCLUSION: Both the LAM+ADV combination therapy and ETV monotherapy exhibited significantly more effective virologic responses compared to the ADV monotherapy in children and adolescents with LAM-resistant chronic hepatitis B, although there was no significant difference between the LAM+ADV group and the ETV group.

StephenW

中华小儿胃肠NUTR。 2012年俊8。 [出处提前打印]
病毒学反应阿德福韦酯治疗与恩替卡韦单药治疗拉米夫定耐药的慢性乙型肝炎的儿童
楚男，赵SM，崔波黑，赵氢，小号权，李星期。
源

儿科†预防医学，大邱，庆北国立大学医学院，韩国。
抽象
目的：

为了比较病毒学应答，阿德福韦（ADV），添加治疗与恩替卡韦（ETV）单一开关与发展Lam治疗拉米夫定（LAM）抗慢性乙型肝炎的儿童和青少年。
方法：

谁制定了Lam治疗拉米夫定耐药的慢性乙型肝炎的二十七名患者都包括在内。这27例患者中，除了正在进行的议员和8名患者被切换到ETV的单一和这16例患者治疗阿德福韦治疗8例患者进行了比较，11人被切换到ADV单治疗的患者，作为一个历史对照。测量递减的HBV DNA滴度在12，24，36，48周的治疗反应进行了评估，从开始治疗。
结果：

治疗期间HBV DNA滴度递减（> 2log10国际单位/毫升）是蓝+动词组，ETV组显着短于在ADV组（P = 0.008）。然而，有Lam+ ADV组和ETV组之间无显着差异。病毒学应答率，定义为递减，在24周时HBV DNA滴度检测不到的水平明显高于Lam+Adv组，ETV组在ADV组（P = 0.029）。
结论：

同时Lam+ ADV联合治疗和ETV单一，表现出明显更有效的病毒学反应相比，在Lam抗慢性乙型肝炎的儿童和青少年进阶单一，虽然有Lam+ ADV组和ETV组之间没有显着差异。